Teladoc Health (NYSE:TDOC) Price Target Lowered to $21.00 at Oppenheimer

Teladoc Health (NYSE:TDOC) had its price target decreased by Oppenheimer from $26.00 to $21.00 in a report published on Friday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the health services provider’s stock.

Other research analysts have also issued reports about the company. Canaccord Genuity Group lowered their price target on Teladoc Health from $28.00 to $25.00 and set a buy rating on the stock in a report on Friday. Truist Financial decreased their target price on Teladoc Health from $23.00 to $17.00 and set a hold rating for the company in a research note on Wednesday, March 6th. Cantor Fitzgerald initiated coverage on Teladoc Health in a research note on Thursday, February 29th. They set an overweight rating and a $22.00 target price for the company. Piper Sandler decreased their target price on Teladoc Health from $30.00 to $25.00 and set an overweight rating for the company in a research note on Wednesday, February 21st. Finally, Royal Bank of Canada decreased their target price on Teladoc Health from $25.00 to $18.00 and set an outperform rating for the company in a research note on Friday. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $19.67.

Teladoc Health Stock Down 2.4 %

Shares of TDOC opened at $13.01 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. Teladoc Health has a one year low of $12.65 and a one year high of $30.41. The stock’s fifty day moving average is $15.01 and its 200-day moving average is $17.77.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. Teladoc Health’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period last year, the business posted ($0.37) earnings per share. Analysts forecast that Teladoc Health will post -1.07 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now owns 57,223 shares of the company’s stock, valued at approximately $1,097,537.14. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the completion of the sale, the insider now directly owns 57,223 shares in the company, valued at approximately $1,097,537.14. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $54,667.80. Following the sale, the chief accounting officer now owns 18,077 shares of the company’s stock, valued at $262,478.04. The disclosure for this sale can be found here. Insiders have sold a total of 135,441 shares of company stock valued at $2,038,251 in the last 90 days. 1.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. ICA Group Wealth Management LLC acquired a new position in shares of Teladoc Health during the fourth quarter worth approximately $28,000. Hexagon Capital Partners LLC lifted its holdings in shares of Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after buying an additional 1,065 shares during the last quarter. RIA Advisory Group LLC acquired a new position in shares of Teladoc Health during the fourth quarter worth approximately $36,000. GAMMA Investing LLC acquired a new position in shares of Teladoc Health during the fourth quarter worth approximately $41,000. Finally, Principal Securities Inc. acquired a new position in shares of Teladoc Health during the fourth quarter worth approximately $45,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.